Pembrolizumab-associated sarcoidosis

JAAD Case Reports

Volumn 2, Issue 4, 2016, Pages 290-293

  Cotliar, Jonathan ^a   Raja, Naveen ^a   Raz, Dan ^a   Boswell, William J ^a   Chen, Robert ^a   Querfeld, Christiane ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

lymphoma; pembrolizumab; programmed cell death 1; sarcoidosis

Indexed keywords

PEMBROLIZUMAB; PREDNISONE;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; EYE PAIN; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MEDIASTINOSCOPY; MICROSCOPY; PANCREATITIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUNCH BIOPSY; SARCOIDOSIS; SUBCUTANEOUS NODULE; THORAX RADIOGRAPHY; TREATMENT WITHDRAWAL;

EID: 84979502853     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2016.06.004     Document Type: Article

References (10)

1. 1 Naidoo, J., Page, D.B., Li, B.T., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26 (2015), 2375–2391.
2. 2 Matsumura, N., Ohtsuka, M., Kikuchi, N., Yamamoto, T., Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. Acta Derm Venereol 96 (2016), 259–260.
3. 3 Kato, Y., Otsuka, A., Miyachi, Y., Kabashima, K., Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol, 2015.
4. 4 Ohtsuka, M., Miura, T., Mori, T., Ishikawa, M., Yamamoto, T., Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma. JAMA Dermatol 151 (2015), 797–799.
5. 5 Goldinger, S.M., Stieger, P., Meier, B., et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res, 2016 [Epub ahead of print].
6. 6 Hwang, S.J., Carlos, G., Wakade, D., et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 74 (2016), 455–461.
7. 7 Sanlorenzo, M., Vujic, I., Daud, A., et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 151 (2015), 1206–1212.
8. 8 Maul, L.V., Weichenthal, M., Kahler, K.C., Hauschild, A., Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease. J Immunother 39 (2016), 188–190.
9. 9 Vincent Lau, K.H., Kumar, A., Yang, I.H., Nowak, R.J., Exacerbation of Myasthenia Gravis in a Patient with Melanoma Treated with Pembrolizumab. Muscle Nerve 54 (2016), 157–161.
10. 10 Naidoo, J., Schindler, K., Querfeld, C., et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res 4 (2016), 383–389.